Yükleniyor... / Loading...
This study investigates the biomarkers and clinical features of metastatic breast cancer in patients treated with CDK4/6 inhibitors. It enrolls adult patients with ER-positive/HER2-negative metastatic or high-risk early-stage breast cancer who are receiving or have received CDK4/6-based therapy. This is a study without an assigned phase and is still recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * All adult patients with ER+/HER2- metastatic breast cancer or HR+/HER2-node positive, high risk early breast cancer who are being or have been treated with ciclib-based therapies are eligible for inclusion in this study * This includes patients receiving standard of care therapy for ER+/HER2- metastatic breast cancer, as well as those who would be eligible to participate in a non-interventional study while on a clinical study open at Roswell Park or St. Vincent's Hospital * Screening will occur in breast oncology clinic, by review of patient medical records for the pending, ongoing, or past treatment with ciclib-based therapy * Participant must understand the prospective nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form Exclusion Criteria: * Pregnant of nursing female subjects * Unwilling or unable to follow protocol requirements